Log in

Novartis Stock Price, News & Analysis (NYSE:NVS)

$86.60
+0.67 (+0.78 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$86.52
Now: $86.60
$87.18
50-Day Range
$84.11
MA: $87.66
$90.11
52-Week Range
$72.19
Now: $86.60
$95.00
Volume1.12 million shs
Average Volume1.82 million shs
Market Capitalization$198.47 billion
P/E Ratio17.01
Dividend Yield2.14%
Beta0.59
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone011-41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.90 billion
Cash Flow$8.21 per share
Book Value$34.07 per share

Profitability

Net Income$12.61 billion

Miscellaneous

Employees125,161
Outstanding Shares2,291,800,000
Market Cap$198.47 billion
Next Earnings Date10/22/2019 (Confirmed)
OptionableOptionable

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.


Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Thursday, January 31st. Investors of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a positive change from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings results on Thursday, July, 18th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.14. The company earned $11.76 billion during the quarter, compared to analysts' expectations of $11.45 billion. Novartis had a net margin of 23.27% and a return on equity of 18.55%. The firm's quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.29 EPS. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

12 analysts have issued 12 month target prices for Novartis' shares. Their predictions range from $79.16 to $105.00. On average, they anticipate Novartis' stock price to reach $91.94 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Has Novartis been receiving favorable news coverage?

Media coverage about NVS stock has trended negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novartis earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Novartis.

Are investors shorting Novartis?

Novartis saw a drop in short interest in September. As of September 30th, there was short interest totalling 3,110,000 shares, a drop of 13.1% from the August 30th total of 3,580,000 shares. Based on an average daily trading volume, of 2,000,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.1% of the shares of the company are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), Walt Disney (DIS), AbbVie (ABBV), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Gilead Sciences (GILD) and Merck & Co., Inc. (MRK).

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

Who are Novartis' major shareholders?

Novartis' stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.11%), Country Trust Bank (0.01%), Gofen & Glossberg LLC IL (0.01%), Scout Investments Inc. (0.01%), Park National Corp OH (0.01%) and Welch & Forbes LLC (0.00%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Manning & Napier Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Country Trust Bank, Park National Corp OH, Stonebridge Capital Management Inc. and Measured Wealth Private Client Group LLC.

Which institutional investors are buying Novartis stock?

NVS stock was purchased by a variety of institutional investors in the last quarter, including Clarus Wealth Advisors, Pacer Advisors Inc., Grassi Investment Management, We Are One Seven LLC, Bangor Savings Bank, Baldwin Brothers Inc. MA, North Star Investment Management Corp. and Courier Capital LLC.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $86.60.

How big of a company is Novartis?

Novartis has a market capitalization of $198.47 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

What is Novartis' official website?

The official website for Novartis is http://www.novartis.com/.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NYSE NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  461 (Vote Outperform)
Underperform Votes:  525 (Vote Underperform)
Total Votes:  986
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel